Compare LSAK & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSAK | PEPG |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.0M | 317.6M |
| IPO Year | N/A | 2022 |
| Metric | LSAK | PEPG |
|---|---|---|
| Price | $4.64 | $5.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.80 |
| AVG Volume (30 Days) | 77.5K | ★ 684.0K |
| Earning Date | 02-04-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $677,582,000.00 | N/A |
| Revenue This Year | $11.97 | N/A |
| Revenue Next Year | $9.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $3.39 | $0.88 |
| 52 Week High | $5.20 | $7.80 |
| Indicator | LSAK | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 48.17 |
| Support Level | $4.47 | $4.83 |
| Resistance Level | $4.72 | $6.20 |
| Average True Range (ATR) | 0.23 | 0.66 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 51.43 | 26.94 |
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates three reportable segments: Merchant, Consumer and Enterprise. Merchant, which focuses on both formal and informal sector merchants. Consumer, which focuses on individuals who have historically been excluded from traditional financial services and to whom it offers transactional accounts (banking), insurance, lending (short-term loans), payments solutions and various value-added services; and Enterprise, which comprises large-scale corporate and government organizations, including but not limited to banks, mobile network operators (MNOs) and municipalities, and, through Recharger, landlords utilizing Recharger's prepaid electricity metering solution.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.